AbbVie Announces New Data on VIEKIRA PAK® (ombitasvir, paritaprevir, ritonavir tablets; dasabuvir tablets) in Patients with Chronic Hepatitis C Virus Infection With or Without Compensated Cirrhosis - Ongoing TOPAZ-II study evaluates long-term treatment outcomes in genotype 1a and genotype 1b chronic HCV patients with or without compensated cirrhosis- Patients treated with VIEKIRA PAK, with or without ribavirin, achieved 95 percent sustained virologic response rates at 12 weeks post-treatment (SVR12)

NORTH CHICAGO, Ill., Nov. 14, 2015 /PRNewswire/ -- AbbVie (NYSE: ABBV), a global biopharmaceutical company, today announced new data from its ongoing Phase 3b TOPAZ-II study evaluating VIEKIRA PAK® (ombitasvir, paritaprevir, ritonavir tablets; dasabuvir tablets), with or without ribavirin (RBV), in adult patients with genotype 1a (GT1a) or genotype 1b (GT1b) chronic hepatitis C virus (HCV) infection.1 Results show that 95 percent (n=586/615) of patients in the TOPAZ-II trial achieved a sustained virologic response at 12 weeks post-treatment (SVR12) after 12 or 24 weeks of treatment, a secondary endpoint for the study.1 These data were presented today at The Liver Meeting®...